 Adrenocortical Carcinoma
"Adrenocortical Carcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
| Descriptor ID |
D018268
|
| MeSH Number(s) |
C04.557.470.200.025.152 C04.588.322.078.265.750 C19.053.098.265.750 C19.053.347.500.750 C19.344.078.265.750
|
| Concept/Terms |
Adrenocortical Carcinoma- Adrenocortical Carcinoma
- Adrenocortical Carcinomas
- Carcinomas, Adrenocortical
- Carcinoma, Adrenocortical
- Carcinoma, Adrenal Cortical
- Adrenal Cortical Carcinoma
- Adrenal Cortical Carcinomas
- Carcinomas, Adrenal Cortical
|
Below are MeSH descriptors whose meaning is more general than "Adrenocortical Carcinoma".
Below are MeSH descriptors whose meaning is more specific than "Adrenocortical Carcinoma".
This graph shows the total number of publications written about "Adrenocortical Carcinoma" by people in this website by year, and whether "Adrenocortical Carcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 3 | 0 | 3 | | 2019 | 2 | 0 | 2 | | 2020 | 4 | 0 | 4 | | 2021 | 1 | 0 | 1 | | 2022 | 1 | 0 | 1 | | 2023 | 4 | 0 | 4 | | 2024 | 6 | 1 | 7 | | 2025 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenocortical Carcinoma" by people in Profiles.
-
Srivatsa S, Aldrink JH, Haque MR, Murphy A, Gehle D, Halepota H, Newman EA, Williams K, Mattei P, Johnston WR, Hwang R, Lautz TB, Ayala SA, Piché N, Lemoine CP, Debertin J, Polites SF, Rothstein DH, Riehle KJ, Nchinda N, Malek MM, Rinehardt HN, Gestrich C, Castle SL, Lopez A, Mayes MS, Myers EK, Roach JP, Craig BT, Lal DR, Schuh J, Cromeens BP, Mannava SV, Austin MT, Mayon LK, Kastenberg ZJ, Wallace M, Alexander A, Stellon MA, Le HD, Joshi DS, Chidiac C, Rhee DS, Cameron D, Stetson A, Rich BS, Glick RD, Fialkowski EA, Fowler K, Fareh R, Brown EG, Doyle K, Abril P, Grant C, Dasgupta R, Boehmer C, Mansfield SA. Surgical Management and Outcomes in Pediatric Adrenocortical Carcinoma: A Pediatric Surgical Oncology Research Collaborative Study. Ann Surg Oncol. 2026 Mar; 33(3):2712-2728.
-
Subramanian C, McNamara K, Hess D, Croslow SW, Tan Y, Kiseljak-Vassiliades K, Wierman ME, Sweedler JV, Cohen MS. A novel therapeutic approach to adrenocortical carcinoma repurposing fingolimod to target sphingolipid metabolism in metastatic disease. Surgery. 2026 Jan; 189:109702.
-
Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Taniyama D, Patel M, Aber E, Contreras CF, Kaplan RN, Kiseljak-Vassiliades K, Wierman ME, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Del Rivero J, Roper N. Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. Nat Commun. 2025 Jul 01; 16(1):5511.
-
Schiavon A, Saba L, Evaristo C, Petiti J, Pignochino Y, Ferrero G, Giordano G, Tucciarello C, Puglisi S, Reimondo G, Terzolo M, Lo Iacono M. Mitotane activates ATF4/ATF3 axis triggering endoplasmic reticulum stress in adrenocortical carcinoma cells. Biomed Pharmacother. 2025 Mar; 184:117917.
-
Subramanian C, McNamara K, Croslow SW, Tan Y, Hess D, Kiseljak-Vassiliades K, Wierman ME, Sweedler JV, Cohen MS. Novel repurposing of sulfasalazine for the treatment of adrenocortical carcinomas, probably through the SLC7A11/xCT-hsa-miR-92a-3p-OIP5-AS1 network pathway. Surgery. 2025 01; 177:108832.
-
Del Rivero J, Else T, Hallanger-Johnson J, Kiseljak-Vassiliades K, Raj N, Reidy-Lagunes D, Srinivas S, Gilbert J, Vaidya A, Aboujaoude E, Bancos I, Tito Fojo A. A review of mitotane in the management of adrenocortical cancer. Oncologist. 2024 Sep 06; 29(9):747-760.
-
Arakawa Y, Elloumi F, Varma S, Khandagale P, Jo U, Kumar S, Roper N, Reinhold WC, Robey RW, Takebe N, Gottesman MM, Thomas CJ, Boeva V, Berruti A, Abate A, Tamburello M, Sigala S, Hantel C, Weigand I, Wierman ME, Kiseljak-Vassiliades K, Del Rivero J, Pommier Y. A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples. Cancer Res Commun. 2024 09 01; 4(9):2384-2398.
-
Ziogas IA, Hills-Dunlap JL, Corkum KS, Cost NG, Gosain A, Roach JP. Current Management Strategies and Outcomes in Children With Adrenocortical Carcinoma. J Surg Res. 2024 Sep; 301:110-117.
-
Scatolini M, Grisanti S, Tomaiuolo P, Grosso E, Basile V, Cosentini D, Puglisi S, Laganà M, Perotti P, Saba L, Rossini E, Palermo F, Sigala S, Volante M, Berruti A, Terzolo M. Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma. Eur J Cancer. 2024 Jul; 205:114088.
-
Wierman ME. Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer? Lancet Oncol. 2024 05; 25(5):534-535.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|